fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

EAHP 2012 Report – Compassionate use and off-label medicines

Written by | 3 Aug 2012

by Zara Qadir reporting on the presentation by Yechiel Hekster (pictured), Professor of Clinical Pharmacy, and a member of The Netherlands Medicines Evaluation Board.

EAHP 2012 Report – Interview with Dr Chantal Bélorgey

Written by | 3 Aug 2012

Zara Qadir interviews Dr Chantal Bélorgey (pictured), Head of Clinical Trial Development at the French national competent authority, Affsaps (Agence française de sécurité sanitaire des produits).

ASCO 2012 Report – Olanzapine appears to control breakthrough chemotherapy-induced nausea and vomiting

Written by | 31 Jul 2012

by Bruce Sylvester – Investigators from a Phase III trial reported at ASCO that chemotherapy-induced nausea and vomiting (CINV) which is unresponsive to conventional treatments reponds to olanzapine… read more.

ASCO 2012 Report – Combination targeted therapy shows efficacy and fewer toxicities in advanced melanoma treatment

Written by | 31 Jul 2012

by Bruce Sylvester – Results from an expanded Phase IB trial presented at ASCO suggest that combination therapy with two investigational and targeted drugs, BRAF inhibitor dabrafenib and… read more.

ASCO 2012 Report – Combination Lenalidomide (Revlimid)/ Rituximab (Rituxan) improves response rate in patients with relapsed follicular lymphoma

Written by | 31 Jul 2012

by Bruce Sylvester – Investigators reported at ASCO that relapsed follicular lymphoma patinets treated with combination lenalidomide (Revlimid) and rituximab (Rituxan) achieved a higher percentage of overall response… read more.

Duloxetine relieves chemotherapy-related neuropathy

Written by | 31 Jul 2012

The antidepressant duloxetine (Cymbalta ®) can effectively treat chemotherapy-induced neuropathy in some patients , researchers reported on July 3, 2012 at the American Society of Clinical Oncology Annual… read more.

New guidelines on Parkinson’s and antibacterials

Written by | 31 Jul 2012

by Gary Finnegan – Emerging uses of EMA Approved Drugs – The European Medicines Agency has updated its guidelines for pharmaceutical companies developing medicines for Parkinson’s disease.

Green light for use of child vaccine outside EU

Written by | 31 Jul 2012

by Gary Finnegan – Emerging uses of EMA Approved Drugs – The European Medicines Agency (EMA) has given its backing to the use of a Hexaxim outside the… read more.

Pazopanib prolongs progression-free survival in patients with advanced soft-tissue Sarcoma

Written by | 31 Jul 2012

by Bruce Sylvester – Emerging uses of FDA Approved Drugs – Treatment with pazopanib nearly tripled progression-free survival (PFS), compared with placebo, among patients with metastatic soft-tissue sarcoma… read more.

Hormone-depleting drug appears to have efficacy in localized high-risk prostate tumors

Written by | 31 Jul 2012

by Bruce Sylvester – Emerging uses of FDA Approved Drugs – A hormone-depleting drug approved in 2011 for the treatment of metastatic prostate cancer appears to help eliminate… read more.

Prednisolone reduces sequelae in Bell’s Palsy

Written by | 31 Jul 2012

by Bruce Sylvester – Emerging uses of FDA Approved Drugs – Patients treated  for Bell palsy with prednisolone within 72 hours achieved  significantly reduced severity of  mild to… read more.

Prednisolone reduces sequelae in Bell's Palsy

Written by | 31 Jul 2012

by Bruce Sylvester – Emerging uses of FDA Approved Drugs – Patients treated  for Bell palsy with prednisolone within 72 hours achieved  significantly reduced severity of  mild to… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.